Frederick S Kaplan

List of Publications by Year
in descending order

200	13,267	19657 61	24982 109
papers	citations	h-index	g-index

208	208	208	6338
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective. Orphanet Journal of Rare Diseases, 2022, 17, 168.	2.7	6
2	Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles. Human Gene Therapy, 2022, 33, 782-788.	2.7	6
3	Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP). Developmental Biology, 2021, 470, 136-146.	2.0	7
4	Surgical and Radiological Management of Complicated Uterine Leiomyoma Aided by 3D Models in a Patient with Fibrodysplasia Ossificans Progressiva. American Journal of Case Reports, 2021, 22, e931614.	0.8	1
5	<scp>Nonclassic</scp> fibrodysplasia ossificans progressiva: A child from Angola with an <scp>ACVR1^{G328E}</scp> variant. American Journal of Medical Genetics, Part A, 2021, 185, 2572-2575.	1.2	1
6	Garetosmab Reduces Flare-ups in Patients With Fibrodysplasia Ossificans Progressiva. Journal of the Endocrine Society, 2021, 5, A251-A252.	0.2	3
7	Whole-body Computed Tomography Versus Dual Energy Xâ€'ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva. Calcified Tissue International, 2021, 109, 615-625.	3.1	5
8	Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet Journal of Rare Diseases, 2021, 16, 350.	2.7	28
9	Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients. Bone, 2021, 149, 115978.	2.9	0
10	Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva. Bone, 2021, 150, 116016.	2.9	6
11	P068â€ƒAbstract tin soldiers Global FOP patient search. Rheumatology, 2021, 60, .	1.9	0
12	Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop. Frontiers in Endocrinology, 2021, 12, 732728.	3.5	15
13	An ACVR1 R375P pathogenic variant in two families with mild fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2021, , .	1.2	3
14	Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva. Bone, 2020, 130, 115116.	2.9	22
15	Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis. Bone, 2020, 140, 115539.	2.9	26
16	Patients with ACVR1R206H mutations have an increased prevalence of cardiac conduction abnormalities on electrocardiogram in a natural history study of Fibrodysplasia Ossificans Progressiva. Orphanet Journal of Rare Diseases, 2020, 15, 193.	2.7	8
17	The Developmental Phenotype of the Great Toe in Fibrodysplasia Ossificans Progressiva. Frontiers in Cell and Developmental Biology, 2020, 8, 612853.	3.7	9
18	Druggable targets, clinical trial design and proposed pharmacological management in fibrodysplasia ossificans progressiva. Expert Opinion on Orphan Drugs, 2020, 8, 101-109.	0.8	12

#	Article	IF	Citations
19	Epidemiology of the Global Fibrodysplasia Ossificans Progressiva (FOP) Community. Journal of Rare Diseases Research & Treatment, 2020, 5, 31-36.	1.1	25
20	Clearance of Senescent Cells From Injured Muscle Abrogates Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva. Journal of Bone and Mineral Research, 2020, 37, 95-107.	2.8	6
21	SUN-344 Patients with Fibrodysplasia Ossificans Progressiva Have an Increased Prevalence of Cardiac Conduction Abnormalities. Journal of the Endocrine Society, 2020, 4, .	0.2	0
22	Fibrodysplasia Ossificans Progressiva in Three Filipino Children. Acta Medica Philippina, 2020, 54, .	0.1	0
23	OR29-05 A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. Journal of the Endocrine Society, 2020, 4, .	0.2	0
24	Compartment Syndrome of the Thigh in a Patient with Fibrodysplasia Ossificans Progressiva. Journal of Orthopaedic Case Reports, 2020, 10, 103-107.	0.1	0
25	Plasma-Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States. Journal of Bone and Mineral Research, 2020, 37, 475-483.	2.8	4
26	Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet Journal of Rare Diseases, 2019, 14, 98.	2.7	51
27	Severe digital malformations in a rare variant of fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2019, 179, 1310-1314.	1.2	5
28	Cover Image, Volume 179A, Number 7, July 2019. , 2019, 179, .		2
29	Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome. Frontiers in Endocrinology, 2019, 10, 908.	3.5	28
30	Ablation of Gsl± signaling in osteoclast progenitor cells adversely affects skeletal bone maintenance. Bone, 2018, 109, 86-90.	2.9	9
31	A case report of mesenteric heterotopic ossification: Histopathologic and genetic findings. Bone, 2018, 109, 56-60.	2.9	6
32	ECSIT links TLR and BMP signaling in FOP connective tissue progenitor cells. Bone, 2018, 109, 201-209.	2.9	18
33	Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 124-133.	2.9	14
34	Vascular ossification: Pathology, mechanisms, and clinical implications. Bone, 2018, 109, 28-34.	2.9	35
35	Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. Bone, 2018, 109, 276-280.	2.9	34
36	Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 158-161.	2.9	9

#	Article	IF	Citations
37	Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 153-157.	2.9	8
38	Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 115-119.	2.9	14
39	Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva. Bone, 2018, 109, 104-110.	2.9	18
40	Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva. Journal of Bone and Mineral Research, 2018, 33, 269-282.	2.8	118
41	Clinical staging of Fibrodysplasia Ossificans Progressiva (FOP). Bone, 2018, 109, 111-114.	2.9	21
42	Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 259-266.	2.9	24
43	Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable. Bone, 2018, 109, 147-152.	2.9	20
44	Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases. Bone, 2018, 109, 281-284.	2.9	18
45	Prevalence and risk factors for kidney stones in fibrodysplasia ossificans progressiva. Bone, 2018, 109, 120-123.	2.9	9
46	Reply to: Macrophages Driving Heterotopic Ossification: Convergence of Genetically-Driven and Trauma-Driven Mechanisms. Journal of Bone and Mineral Research, 2018, 33, 367-368.	2.8	0
47	Fibrodysplasia (Myositis) Ossificans Progressiva. , 2018, , 523-545.		2
48	Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 218-224.	2.9	36
49	The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva. Bone, 2018, 109, 285-290.	2.9	19
50	BMP Signaling in Fibrodysplasia Ossificans Progressiva, a Rare Genetic Disorder of Heterotopic Ossification. , 2017, , 327-343.		0
51	The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call. European Journal of Medical Genetics, 2017, 60, 399-402.	1.3	9
52	A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone, 2017, 101, 123-128.	2.9	41
53	GsÎ± Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and Î²-Catenin Pathways. Scientific Reports, 2017, 7, 45140.	3.3	24
54	Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva. Academic Radiology, 2017, 24, 321-327.	2.5	8

#	Article	IF	Citations
55	Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opinion on Orphan Drugs, 2017, 5, 291-294.	0.8	34
56	International physician survey on management of FOP: a modified Delphi study. Orphanet Journal of Rare Diseases, 2017, 12, 110.	2.7	15
57	Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. Journal of Bone and Mineral Research, 2016, 31, 1652-1665.	2.8	110
58	ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva. Bone, 2016, 92, 29-36.	2.9	15
59	The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment. Journal of Bone and Mineral Research, 2016, 31, 650-656.	2.8	157
60	Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation. Journal of Bone and Mineral Research, 2016, 31, 1666-1675.	2.8	137
61	Granting immunity to FOP and catching heterotopic ossification in the Act. Seminars in Cell and Developmental Biology, 2016, 49, 30-36.	5.0	54
62	ACVR1 and Fibrodysplasia Ossificans Progressiva. , 2016, , 435-438.		0
63	Multiâ€system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1) Tj ETQq1 1 0.784314 rgBT /Ov 2265-2271.	1.2	33
64	Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. The Application of Clinical Genetics, 2015, 8, 37.	3.0	67
65	The Immunological Contribution to Heterotopic Ossification Disorders. Current Osteoporosis Reports, 2015, 13, 116-124.	3.6	66
66	Alk2 Regulates Early Chondrogenic Fate in Fibrodysplasia Ossificans Progressiva Heterotopic Endochondral Ossification. Stem Cells, 2014, 32, 1289-1300.	3.2	94
67	General Anesthesia for Dental Procedures in Patients with Fibrodysplasia Ossificans Progressiva. Anesthesia and Analgesia, 2014, 118, 298-301.	2.2	30
68	ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant. Human Molecular Genetics, 2014, 23, 5364-5377.	2.9	48
69	Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification. Nature Medicine, 2013, 19, 1505-1512.	30.7	187
70	The phenotype and genotype of fibrodysplasia ossificans progressiva in China: A report of 72 cases. Bone, 2013, 57, 386-391.	2.9	56
71	The skeleton in the closet. Gene, 2013, 528, 7-11.	2.2	9
72	From mysteries to medicines: drug development for fibrodysplasia ossificans progressiva. Expert Opinion on Orphan Drugs, 2013, 1, 637-649.	0.8	34

#	Article	IF	Citations
73	Fibrodysplasia (Myositis) Ossificans Progressiva. , 2013, , 375-393.		5
74	Somitic disruption of GNAS in chick embryos mimics progressive osseous heteroplasia. Journal of Clinical Investigation, 2013, 123, 3624-3633.	8.2	45
75	Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 437-48.	1.2	59
76	Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. DMM Disease Models and Mechanisms, 2012, 5, 756-762.	2.4	109
77	Pregnancy in fibrodysplasia ossificans progressiva. Obstetric Medicine, 2012, 5, 35-38.	1.1	5
78	Severe soft tissue ossification in a southern right whale Eubalaena australis. Diseases of Aquatic Organisms, 2012, 102, 149-156.	1.0	6
79	Neurological symptoms in individuals with fibrodysplasia ossificans progressiva. Journal of Neurology, 2012, 259, 2636-2643.	3.6	39
80	CNS demyelination in fibrodysplasia ossificans progressiva. Journal of Neurology, 2012, 259, 2644-2655.	3.6	37
81	The complex craniofacial signature of fibrodysplasia ossificans progressiva: Whose handwriting is it?. American Journal of Medical Genetics, Part A, 2012, 158A, 2979-2980.	1.2	0
82	Functional Analysis of Alleged NOGGIN Mutation G92E Disproves Its Pathogenic Relevance. PLoS ONE, 2012, 7, e35062.	2.5	2
83	Extraskeletal Bone Formation. , 2012, , 821-840.		0
84	Paternally Inherited Gsî± Mutation Impairs Adipogenesis and Potentiates a Lean Phenotype In Vivo. Stem Cells, 2012, 30, 1477-1485.	3.2	24
85	An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. Journal of Bone and Mineral Research, 2012, 27, 1746-1756.	2.8	157
86	The face signature of fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2012, 158A, 1368-1380.	1.2	38
87	Derailing heterotopic ossification and RARing to go. Nature Medicine, 2011, 17, 420-421.	30.7	19
88	Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis. Annals of the New York Academy of Sciences, 2011, 1237, 5-10.	3.8	31
89	Role of Altered Signal Transduction in Heterotopic Ossification and Fibrodysplasia Ossificans Progressiva. Current Osteoporosis Reports, 2011, 9, 83-88.	3.6	30
90	Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects. Orphanet Journal of Rare Diseases, 2011, 6, 80.	2.7	231

#	Article	IF	Citations
91	Heterozygous inactivation of Gnas in adipose-derived mesenchymal progenitor cells enhances osteoblast differentiation and promotes heterotopic ossification. Journal of Bone and Mineral Research, 2011, 26, 2647-2655.	2.8	68
92	Substance P signaling mediates BMP-dependent heterotopic ossification. Journal of Cellular Biochemistry, 2011, 112, 2759-2772.	2.6	99
93	In vitro Analyses of the Dysregulated R206H ALK2 Kinase-FKBP12 Interaction Associated with Heterotopic Ossification in FOP. Cells Tissues Organs, 2011, 194, 291-295.	2.3	65
94	Fibrodysplasia ossificans progressiva (FOP): watch the great toes!. European Journal of Pediatrics, 2010, 169, 1417-1421.	2.7	28
95	Viewing FOP through rosi-colored glasses. Journal of Bone and Mineral Research, 2010, 25, 2295-2296.	2.8	0
96	Conversion of vascular endothelial cells into multipotent stem-like cells. Nature Medicine, 2010, 16, 1400-1406.	30.7	635
97	Early Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2010, 92, 686-691.	3.0	169
98	Investigations of Activated ACVR1/ALK2, a Bone Morphogenetic Protein Type I Receptor, That Causes Fibrodysplasia Ossificans Progressiva. Methods in Enzymology, 2010, 484, 357-373.	1.0	16
99	Inherited human diseases of heterotopic bone formation. Nature Reviews Rheumatology, 2010, 6, 518-527.	8.0	220
100	Fibrodysplasia Ossificans Progressiva: Developmental Implications of a Novel Metamorphogene. , 2010, , 233-249.		8
101	Osteochondral Diseases and Fibrodysplasia Ossificans Progressiva. Advances in Experimental Medicine and Biology, 2010, 686, 335-348.	1.6	19
102	Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva. Journal of Biological Chemistry, 2009, 284, 7149-7156.	3.4	184
103	Chin-on-Chest Deformity in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2009, 91, 1497-1502.	3.0	24
104	Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Human Mutation, 2009, 30, 379-390.	2.5	364
105	The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine and Growth Factor Reviews, 2009, 20, 399-407.	7.2	60
106	Identification of Progenitor Cells That Contribute to Heterotopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2009, 91, 652-663.	3.0	278
107	The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. Journal of Clinical Investigation, 2009, 119, 3462-72.	8.2	178
108	Dysregulated BMP Signaling and Enhanced Osteogenic Differentiation of Connective Tissue Progenitor Cells From Patients With Fibrodysplasia Ossificans Progressiva (FOP). Journal of Bone and Mineral Research, 2008, 23, 305-313.	2.8	135

#	Article	IF	Citations
109	Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). Journal of Bone and Mineral Metabolism, 2008, 26, 521-530.	2.7	73
110	Fibrodysplasia ossificans progressiva. Best Practice and Research in Clinical Rheumatology, 2008, 22, 191-205.	3.3	310
111	When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP). Drug Discovery Today: Therapeutic Strategies, 2008, 5, 255-262.	0.5	18
112	Key to the kingdom: the challenge of rare diseases. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 233-235.	0.5	0
113	Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone, 2008, 43, 427-433.	2.9	117
114	Early Diagnosis of Fibrodysplasia Ossificans Progressiva. Pediatrics, 2008, 121, e1295-e1300.	2.1	151
115	Lumbar puncture and surgical intervention in a child with undiagnosed fibrodysplasia ossificans progressiva. Journal of Neurosurgery: Pediatrics, 2008, 1, 91-94.	1.3	17
116	Proximal Tibial Osteochondromas in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2008, 90, 366-374.	3.0	71
117	Hematopoietic Stem-Cell Contribution to Ectopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2007, 89, 347-357.	3.0	102
118	Focal Fibronodular Heterotopic Ossification. Journal of Bone and Joint Surgery - Series A, 2007, 89, 1329-1336.	3.0	2
119	Heparan Sulfate Proteoglycans (HSPGs) Modulate BMP2 Osteogenic Bioactivity in C2C12 Cells. Journal of Biological Chemistry, 2007, 282, 1080-1086.	3.4	143
120	Progressive osseous heteroplasia-like heterotopic ossification in a male infant with pseudohypoparathyroidism type Ia: A case report. Bone, 2007, 40, 1425-1428.	2.9	30
121	A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opinion on Biological Therapy, 2007, 7, 705-712.	3.1	50
122	Functional Modeling of the ACVR1 (R206H) Mutation in FOP. Clinical Orthopaedics and Related Research, 2007, 462, 87-92.	1.5	86
123	Over-expression ofBMP4 andBMP5 in a child with axial skeletal malformations and heterotopic ossification: A new syndrome. American Journal of Medical Genetics, Part A, 2007, 143A, 699-706.	1.2	17
124	HSPG modulation of BMP signaling in fibrodysplasia ossificans progressiva cells. Journal of Cellular Biochemistry, 2007, 102, 1493-1503.	2.6	18
125	Morphogen Receptor Genes and Metamorphogenes: Skeleton Keys to Metamorphosis. Annals of the New York Academy of Sciences, 2007, 1116, 113-133.	3.8	42
126	Hematopoietic Stem-Cell Contribution to Ectopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2007, 89, 347-357.	3.0	81

#	Article	IF	Citations
127	Focal Fibronodular Heterotopic Ossification. Journal of Bone and Joint Surgery - Series A, 2007, 89, 1329-1336.	3.0	2
128	Heterotopic Ossification in the Mesentery After Abdominal Surgery. , 2006, 16, 323-328.		2
129	A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics, 2006, 38, 525-527.	21.4	1,079
130	Dysregulation of the BMP-4 Signaling Pathway in Fibrodysplasia Ossificans Progressiva. Annals of the New York Academy of Sciences, 2006, 1068, 54-65.	3.8	65
131	Dysregulation of the BMP-p38 MAPK Signaling Pathway in Cells From Patients With Fibrodysplasia Ossificans Progressiva (FOP). Journal of Bone and Mineral Research, 2006, 21, 902-909.	2.8	97
132	Developmental Anomalies of the Cervical Spine in Patients With Fibrodysplasia Ossificans Progressiva Are Distinctly Different From Those in Patients With Klippel-Feil Syndrome. Spine, 2005, 30, 1379-1385.	2.0	89
133	Fibrodysplasia Ossificans Progressiva (FOP), a Disorder of Ectopic Osteogenesis, Misregulates Cell Surface Expression and Trafficking of BMPRIA. Journal of Bone and Mineral Research, 2005, 20, 1168-1176.	2.8	103
134	Fibrodysplasia Ossificans Progressiva: An Historical Perspective. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 179-182.	0.8	9
135	The Phenotype of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 183-188.	0.8	94
136	Immunological Features of Fibrodysplasia Ossificans Progressiva and the Dysregulated BMP4 Pathway. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 189-194.	0.8	45
137	The Fibrodysplasia Ossificans Progressiva Lesion. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 195-200.	0.8	65
138	The Genetics of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 201-204.	0.8	98
139	Three Pairs of Monozygotic Twins With Fibrodysplasia Ossificans Progressiva: <I>The Role of Environment in the Progression of Heterotopic Ossification</I>. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 205-208.	0.8	41
140	The Craniofacial Phenotype of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 209-212.	0.8	8
141	Thoracic Insufficiency Syndrome in Patients With Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 213-216.	0.8	63
142	Dysregulation of BMP4 Receptor Trafficking and Signaling in Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 217-224.	0.8	8
143	Early Fibrodysplasia Ossificans Progressiva-Like Lesion Formation in Nude Mice Following Implantation of Lymphoblastoid Cells From FOP Patients. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 225-228.	0.8	0
144	Animal Models of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 229-234.	0.8	11

#	Article	IF	Citations
145	Oral and Dental Health Care and Anesthesia for Persons With Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 239-242.	0.8	24
146	Treatment Considerations for the Management of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 243-250.	0.8	39
147	Fibrodysplasia Ossificans Progressiva and Progressive Osseous Heteroplasia: <I>Two Genetic Disorders of Heterotopic Ossification</I>. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 257-260.	0.8	13
148	Iatrogenic Harm Caused by Diagnostic Errors in Fibrodysplasia Ossificans Progressiva. Pediatrics, 2005, 116, e654-e661.	2.1	203
149	Influenza-like Viral Illnesses and Flare-ups of Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2004, 423, 275-279.	1.5	68
150	Heterotopic Ossification. Journal of the American Academy of Orthopaedic Surgeons, The, 2004, 12, 116-125.	2.5	307
151	Progressive osseous heteroplasia in the face of a child. American Journal of Medical Genetics Part A, 2003, 118A, 71-75.	2.4	20
152	Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification?. Journal of Pathology, 2003, 201, 141-148.	4.5	59
153	Bone Morphogenetic Protein-4 Regulation in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2003, 408, 331-343.	1.5	43
154	Exoneration of NF-??B Dysregulation in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2003, 406, 205-213.	1.5	6
155	PARESIS OF A BONE MORPHOGENETIC PROTEIN-ANTAGONIST RESPONSE IN A GENETIC DISORDER OF HETEROTOPIC SKELETOGENESIS. Journal of Bone and Joint Surgery - Series A, 2003, 85, 667-674.	3.0	79
156	IN VIVO SOMATIC CELL GENE TRANSFER OF AN ENGINEERED NOGGIN MUTEIN PREVENTS BMP4-INDUCED HETEROTOPIC OSSIFICATION. Journal of Bone and Joint Surgery - Series A, 2003, 85, 2332-2342.	3.0	128
157	Paternally Inherited Inactivating Mutations of theGNAS1Gene in Progressive Osseous Heteroplasia. New England Journal of Medicine, 2002, 346, 99-106.	27.0	284
158	Reported noggin mutations are PCR errors. American Journal of Medical Genetics Part A, 2002, 109, 161-161.	2.4	14
159	Orthopedic Surgery Considerations in Paget's Disease of Bone. Clinical Reviews in Bone and Mineral Metabolism, 2002, 1, 159-166.	0.8	3
160	Mast cell involvement in fibrodysplasia ossificans progressiva. Human Pathology, 2001, 32, 842-848.	2.0	96
161	Bone Formation and Inflammation in Cardiac Valves. Circulation, 2001, 103, 1522-1528.	1.6	922
162	Fibrodysplasia ossificans progressiva. Pediatric Radiology, 2001, 31, 307-314.	2.0	108

#	Article	IF	Citations
163	GNAS1 Mutation and Cbfa1 Misexpression in a Child with Severe Congenital Platelike Osteoma Cutis. Journal of Bone and Mineral Research, 2000, 15, 2063-2073.	2.8	66
164	Deficiency of the Î±-Subunit of the Stimulatory G Protein and Severe Extraskeletal Ossification. Journal of Bone and Mineral Research, 2000, 15, 2074-2083.	2.8	110
165	Progressive Osseous Heteroplasia. Journal of Bone and Mineral Research, 2000, 15, 2084-2094.	2.8	192
166	Fibrodysplasia Ossificans Progressiva, a Heritable Disorder of Severe Heterotopic Ossification, Maps to Human Chromosome 4q27-31*. American Journal of Human Genetics, 2000, 66, 128-135.	6.2	88
167	Fibrodysplasia Ossificans Progressiva. , 2000, , 211-236.		0
168	Conductive Hearing Loss in Individuals with Fibrodysplasia Ossificans Progressiva. American Journal of Audiology, 1999, 8, 29-33.	1.2	47
169	Encrypted morphogens of skeletogenesis. Biochemical Pharmacology, 1998, 55, 373-382.	4.4	29
170	Urinary Basic Fibroblast Growth Factor. Clinical Orthopaedics and Related Research, 1998, 346, 59???65.	1.5	17
171	Catastrophic Falls in Patients Who Have Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 110???116.	1.5	48
172	Characterization of Bone Morphogenetic Protein 4 Receptor in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 38???45.	1.5	24
173	Pulmonary and Cardiac Function in Advanced Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 104???109.	1.5	54
174	Treatment of Patients Who Have Fibrodysplasia Ossificans Progressiva With Isotretinoin. Clinical Orthopaedics and Related Research, 1998, 346, 121???129.	1.5	37
175	Acute Lymphocytic Infiltration in an Extremely Early Lesion of Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 19???25.	1.5	96
176	Embryonic Overexpression of the c-Fos Protooncogene. Clinical Orthopaedics and Related Research, 1998, 346, 81???94.	1.5	6
177	Fibrodysplasia Ossificans Progressiva (FOP): The Value of Studying a Rare Disorder. Drug Information Journal, 1997, 31, 273-277.	0.5	0
178	Limb Swelling in Patients Who Have Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1997, 336, 247-253.	1.5	26
179	Bone morphogenetic protein 24 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Human Pathology, 1997, 28, 339-343.	2.0	115
180	Fibrodysplasia Ossificans Progressiva (FOP). Journal of Bone and Mineral Research, 1997, 12, 855-855.	2.8	20

#	Article	IF	Citations
181	â€œYour Pal, Johnâ€: Calcified Tissue International, 1997, 61, 261-262.	3.1	0
182	Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1996, 81, 21-25.	1.4	99
183	Fibrodysplasia ossificans progressiva in two half-sisters: Evidence for maternal mosaicism. , 1996, 61, 320-324.		28
184	Skin and Bones. Archives of Dermatology, 1996, 132, 815.	1.4	25
185	Overexpression of an Osteogenic Morphogen in Fibrodysplasia Ossificans Progressiva. New England Journal of Medicine, 1996, 335, 555-561.	27.0	364
186	Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. Journal of Pediatrics, 1995, 126, 762-764.	1.8	104
187	Age- and Joint-Specific Risk of Initial Heterotopic Ossification in Patients Who Have Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1994, &NA;, 243???248.	1.5	84
188	Traumatic Fractures of Heterotopic Bone in Patients Who Have Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1994, &NA;, 173???177.	1.5	19
189	Heterotopic Ossification: Two Rare Forms and What They Can Teach Us. Journal of the American Academy of Orthopaedic Surgeons, The, 1994, 2, 288-296.	2.5	78
190	A bone morphogenetic protein subfamily: Chromosomal localization of human genes for BMP5, BMP6, and BMP7. Genomics, 1992, 14, 759-762.	2.9	52
191	The role of morphogens in endochondral ossification. Calcified Tissue International, 1992, 50, 283-289.	3.1	41
192	Bone morphogenetic protein: Chromosomal localization of human genes for BMP1, BMP2A, and BMP3. Genomics, 1991, 9, 283-289.	2.9	77
193	Fibrodysplasia ossificans progressiva: A clue from the fly?. Calcified Tissue International, 1990, 47, 117-125.	3.1	117
194	Observer variation in the detection of osteopenia. Skeletal Radiology, 1986, 15, 347-349.	2.0	37
195	Age-related changes in proprioception and sensation of joint position. Acta Orthopaedica, 1985, 56, 72-74.	1.4	181
196	Fibrodysplasia Ossificans Progressiva. , 0, , 827-840.		20
197	Chapter 94. Fibrodysplasia (Myositis) Ossificans Progressiva. , 0, , 442-446.		1
198	Fibrodysplasia ossificans progressiva: baseline characteristics of 101 subjects participating in a global, longitudinal, natural history study. Bone Abstracts, 0, , .	0.0	0

#	Article	IF	Citations
199	A global natural history study of Fibrodysplasia Ossificans Progressiva (FOP): 12-month outcomes. Endocrine Abstracts, 0, , .	0.0	0
200	Fibrodysplasia Ossificans Progressiva. , 0, , 211-236.		0